Related Experiment Video
Updated: Jan 14, 2026
Genome-Wide Analysis of DNA Methylation in Gastrointestinal Cancer
Published on: September 18, 2020
Biotechnological Insights into KAT2A-Mediated Epigenetic Regulation in Colorectal Cancer: A Transcriptomic and
Kianoush Mohammadi1, Reza Safaralizade1
1Department of Animal Biology, Faculty of Natural Sciences, University of Tabriz, Tabriz, Iran.
Background:
Epigenetic modifiers such as lysine acetyltransferase 2A (KAT2A) have been reported to be the key regulators of gene expression in various cancers, including colorectal cancer (CRC). The transcriptomic effect of KAT2A deficiency in CRC and its implication on cancer-related pathways remains poorly elucidated.
Objectives:
The objective of this research was to investigate genome-wide transcriptional alterations induced by KAT2A knockout in colorectal cancer cells with an eye toward the recognition of putative molecular targets for diagnosis or therapy.
Materials And Methods:
KAT2A-knockout HCT116 cell high-throughput RNA sequencing data (GSE246881) were analyzed. Differentially expressed genes (DEGs) were defined by DESeq2. Functional enrichment analysis, including Gene Ontology (GO) and KEGG pathways, and protein-protein interaction (PPI) network building were performed using integrated bioinformatics tools.
Results:
KAT2A knockout resulted in 626 DEGs, predominantly downregulated, and indicated a potential role of KAT2A as a transcriptional activator. Enrichment analyses revealed significant involvement of cancer-related pathways such as MAPK and mTOR. PPI network analysis revealed key hub genes such as AKT1, VEGFA, and PLEC that are involved in tumor growth and may be future biomarkers or therapeutic targets.
Conclusion:
KAT2A plays a pivotal role in oncogenic signaling pathways in CRC. The identified genes and pathways here present promising prospects for biotechnological application in cancer biomarker identification and targeted therapy, demonstrating the potential of KAT2A-centered regulatory networks in guiding CRC management strategies.
Insights
Lysine acetyltransferase 2A (KAT2A) deficiency in colorectal cancer (CRC) alters gene expression, impacting cancer pathways. Key genes like AKT1 and VEGFA were identified as potential therapeutic targets for CRC.
Area of Science:
- Molecular Biology
- Genomics
- Cancer Research
Background:
- Lysine acetyltransferase 2A (KAT2A) is a key epigenetic regulator in various cancers, including colorectal cancer (CRC).
- The precise transcriptomic impact of KAT2A deficiency in CRC and its role in cancer-related pathways require further elucidation.
Purpose of the Study:
- To investigate genome-wide transcriptional changes caused by KAT2A knockout in colorectal cancer cells.
- To identify potential molecular targets for CRC diagnosis or therapy based on KAT2A's function.
Main Methods:
- High-throughput RNA sequencing of KAT2A-knockout HCT116 cells.
- Differential gene expression analysis using DESeq2.
- Functional enrichment analysis (GO, KEGG) and protein-protein interaction (PPI) network construction.
Main Results:
- KAT2A knockout led to 626 differentially expressed genes (DEGs), mostly downregulated, suggesting KAT2A acts as a transcriptional activator.
- Enrichment analyses highlighted the involvement of cancer-related pathways, including MAPK and mTOR.
- PPI network analysis identified key hub genes (AKT1, VEGFA, PLEC) implicated in tumor growth.
Conclusions:
- KAT2A is crucial in oncogenic signaling pathways within CRC.
- Identified genes and pathways offer potential for developing cancer biomarkers and targeted therapies.
- KAT2A-centered regulatory networks can guide CRC management strategies.
Related Concept Videos
01:37Epigenetic Regulation
X-chromosome...
01:46Epigenetic Regulation